Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)
T-cell PTLDs are lymphoid proliferations that develop in recipients of SOT or allogeneic HSCT. They carry an extremely poor prognosis with a reported median survival of only 6 months. The infrequency with which they are encountered makes treatment a challenge due to the lack of prospective trials to...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/6/426 |
| _version_ | 1797505637272256512 |
|---|---|
| author | Jennifer Hong William T. Johnson Saritha Kartan Anitha S. Gonsalves Jonathan M. Fenkel Jerald Z. Gong Pierluigi Porcu |
| author_facet | Jennifer Hong William T. Johnson Saritha Kartan Anitha S. Gonsalves Jonathan M. Fenkel Jerald Z. Gong Pierluigi Porcu |
| author_sort | Jennifer Hong |
| collection | DOAJ |
| description | T-cell PTLDs are lymphoid proliferations that develop in recipients of SOT or allogeneic HSCT. They carry an extremely poor prognosis with a reported median survival of only 6 months. The infrequency with which they are encountered makes treatment a challenge due to the lack of prospective trials to guide management. The significantly higher risk of morbidity and mortality in T-cell PTLD, compared to B-cell PTLD, underscores the challenge of treating these patients and the need for new therapeutic options. Brentuximab vedotin, an ADC targeting CD30, is FDA-approved in combination with CHP as front-line treatment for patients with CD30 expressing PTCL. Herein we report a case of CD30-positive T-cell PTLD that was successfully treated with BV-CHP, suggesting the added value of the addition of BV to chemotherapy, contributing to our patient’s long and ongoing progression-free survival. To our knowledge, this is the first documented case of successful treatment using BV-CHP for a CD30-positive, EBV-negative, late T-cell PTLD. |
| first_indexed | 2024-03-10T04:21:27Z |
| format | Article |
| id | doaj.art-f48ec0f51b674c91b7968ecd99ed4fff |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T04:21:27Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-f48ec0f51b674c91b7968ecd99ed4fff2023-11-23T07:50:56ZengMDPI AGCurrent Oncology1198-00521718-77292021-12-012865067507210.3390/curroncol28060426Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)Jennifer Hong0William T. Johnson1Saritha Kartan2Anitha S. Gonsalves3Jonathan M. Fenkel4Jerald Z. Gong5Pierluigi Porcu6Department of Hematology and Oncology, Lankenau Medical Center, Wynnewood, PA 19096, USADepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USADepartment of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USADepartment of Radiology, Pottstown Hospital, Pottstown, PA 19464, USADepartment of Gastroenterology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USADepartment of Pathology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USADepartment of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USAT-cell PTLDs are lymphoid proliferations that develop in recipients of SOT or allogeneic HSCT. They carry an extremely poor prognosis with a reported median survival of only 6 months. The infrequency with which they are encountered makes treatment a challenge due to the lack of prospective trials to guide management. The significantly higher risk of morbidity and mortality in T-cell PTLD, compared to B-cell PTLD, underscores the challenge of treating these patients and the need for new therapeutic options. Brentuximab vedotin, an ADC targeting CD30, is FDA-approved in combination with CHP as front-line treatment for patients with CD30 expressing PTCL. Herein we report a case of CD30-positive T-cell PTLD that was successfully treated with BV-CHP, suggesting the added value of the addition of BV to chemotherapy, contributing to our patient’s long and ongoing progression-free survival. To our knowledge, this is the first documented case of successful treatment using BV-CHP for a CD30-positive, EBV-negative, late T-cell PTLD.https://www.mdpi.com/1718-7729/28/6/426post-transplant lymphoproliferative disordersT-cellperipheral T-cell lymphomaNOSCD30brentuximab |
| spellingShingle | Jennifer Hong William T. Johnson Saritha Kartan Anitha S. Gonsalves Jonathan M. Fenkel Jerald Z. Gong Pierluigi Porcu Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD) Current Oncology post-transplant lymphoproliferative disorders T-cell peripheral T-cell lymphoma NOS CD30 brentuximab |
| title | Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD) |
| title_full | Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD) |
| title_fullStr | Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD) |
| title_full_unstemmed | Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD) |
| title_short | Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD) |
| title_sort | durable response to brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone bv chp in a patient with cd30 positive ptcl arising as a post transplant lymphoproliferative disorder ptld |
| topic | post-transplant lymphoproliferative disorders T-cell peripheral T-cell lymphoma NOS CD30 brentuximab |
| url | https://www.mdpi.com/1718-7729/28/6/426 |
| work_keys_str_mv | AT jenniferhong durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld AT williamtjohnson durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld AT sarithakartan durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld AT anithasgonsalves durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld AT jonathanmfenkel durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld AT jeraldzgong durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld AT pierluigiporcu durableresponsetobrentuximabvedotinpluscyclophosphamidedoxorubicinandprednisonebvchpinapatientwithcd30positiveptclarisingasaposttransplantlymphoproliferativedisorderptld |